steroid use was not related to BMD at the wrist or hip in women or at any skeletal Background -Bone mineral density has site in men. Women taking an inhaled been reduced in patients with asthma taksteroid had lower levels of serum osteoing inhaled corticosteroids in some cross calcin than those not taking them, alsectional studies and this could be imthough this was not dose related. Inhaled portant if treatment is continued for steroid use was not associated with differseveral decades. The possibility of conences in other markers of bone metabolism founding by age, menopausal status, physin men or women or with the presence of ical activity and, especially, past oral vertebral fractures. steroid use has not been excluded in most
changes around puberty, and because asthma Diagnostica, Espoo, Finland; Hybridtech Europe, Liege, Belgium; and Nichols Institute, San can delay the onset of puberty. 21 Some studies in adults have included postmenopausal Jan Capistrano, California, USA, respectively).
A 10 ml sample of urine was stored at −80°C women who may have widely differing rates of bone loss. 1 7 9 Although physical activity is before assay for deoxypyridinoline concentration by ELISA (Rowett Research Services, important for skeletal remodelling 22 23 and may be reduced in some patients with asthma, 24 it Aberdeen, UK) and values were corrected for urinary creatinine concentration. has only been assessed in three of the previous studies. 4 6 9 Bone mineral density (g/cm 2 ) of the neck of the non-dominant femur and distal radius, The present study was designed to reduce the chances of confounding by age, menopausal posterior-anterior spine (L2-L4), and lateral spine (body of L3 (B3)) was measured by dual status, and previous use of systemic steroids and to incorporate these factors, differences in energy x ray absorptiometry (DEXA; Lunar DPX-L scanner, Lunar Corporation, Madison, physical activity, and other potential confounding factors into the analysis.
Wisconsin, USA). All scans were carried out by the same radiographer using "fast mode" at 3000 mA unless adjustment was needed for body mass. Routine calibration checks were Methods  carried out in accordance with the manufacturer's specifications including a daily calMen and women aged 20-40 years with a documented history of asthma were recruited ibration check against a three-chambered phantom containing bone ash of known masses. from our asthma register and from local general practices. They were selected according to pre-The coefficients of variation over the period of study for the three chambers were 0.52, 0.51 determined criteria for group 1 if they were using an inhaled 2 agonist only for their asthma and 0.43%, respectively. Lateral radiographs focused on thoracic vertebrae T7 and T9 and and had never received inhaled, systemic, or topical corticosteroids apart from dermal ster-lumbar vertebrae L2 and L3 were taken. Vertebral fractures were classified from the radiooids, and for group 2 if they had used an inhaled steroid for at least five years with no graphs and graded according to the method of Eastell et al 26 by the same radiologist who systemic steroids in the past six months and limited use of systemic steroids in the past. was blind to the patients' treatment. Patients were only included in group 2 if their total exposure to oral steroids over the past five years was less than 2000 mg prednisolone or   Subjects completed a self-administered quesequivalent (plus a maximum daily dose of 60 mg, total duration of treatment <12 weeks, tionnaire. A 20 ml sample of venous blood and a first morning void urine sample were obtained and no more than two courses in one year) and if hydrocortisone by injection did not exceed a between 07.00 and 10.00 hours after a 12 hour fast for routine biochemical screening and total dose of 3200 mg on two occasions. Patients were excluded from both groups if markers of bone metabolism. Spirometric tests, bone mineral density measurements, and latthey had been immobilised for long periods, had a history of alcohol or drug abuse, had eral thoracic and lumbar radiography were then performed. The questionnaire included quesever had a metabolic disease which might affect bone density -for example, diabetes, chronic tions on total pack years of smoking, alcohol consumption (expressed as mean number of renal or hepatic disease -or if they had used drugs known to affect bone metabolism -for units per week over the past five years), number of months milk products were not consumed, example, calcium supplements, sodium fluoride, >400 mg/day vitamin D, calcitonin, bi-and questions relating to the frequency of physical activities (standing, walking and lifting sphosphonates, hormone replacement therapy, anabolic steroids or thiazide diuretics. All heavy objects, frequency of exercise), and self assessment of fitness and strength. Activity was women were premenopausal and said that they were menstruating regularly. The study was graded in five categories of increasing relative magnitude (1=lowest, 5=highest). Details of approved by the Nottingham City Hospital ethics committee and all patients gave written systemic steroid use at any time were also obtained. Women were asked about full term informed consent.
pregnancies, length of time breast feeding, and type and duration of contraceptive hormone use from which a life time dose of oestrogen  Forced expiratory volume in one second and progesterone was derived.
Patients in the inhaled steroid group were (FEV 1 ) and forced vital capacity (FVC) were measured by dry bellows spirometer (Vitalo-asked about type, dose, and duration of inhaled steroid use. If patients temporarily varied the graph Ltd, Buckingham, UK) and FEV 1 was expressed as % predicted.
25 Plasma con-daily number of puffs during an exacerbation of asthma they were asked to estimate the centrations of calcium, phosphate, total protein and albumin and urinary concentrations of average number of puffs per day over the episode and this estimate was then used in the calcium, phosphate, sodium, and creatinine were measured by routine assays. Serum levels calculation of total dose of inhaled steroid. Any change in the formulation or daily number of of procollagen peptide I (PCP-I), bone specific alkaline phosphatase (ostase), and osteocalcin puffs of inhaled steroid was assessed as a new, discrete episode of inhaled steroid use. Inhaled were assayed by radioimmunoassay (Orion budesonide and beclomethasone dipropionate interest, was kept in the model irrespective of its statistical significance. The three measures were assumed to be equipotent and no distinction was made between aerosol or powder of inhaled steroid dose were then added in turn to the final predictive model for each of the formulations, method of delivery, or the use of spacer devices. Standardised cumulative in-sites at which BMD had been measured. The effects of inhaled steroid use (dose or duration) haled steroid dose was expressed as mg/day. years -for example, 500 g/day for two years= were considered to be statistically significant when p<0.05. Finally, the potential con-1 mg/day.year. Oral steroid use was expressed as the number of courses ever (because precise founders not so far included in each model were added singly to verify that they had no details of duration were not always available) and parenteral steroids as total life time dose substantial influence on the estimated effect of inhaled steroid use. (mg). Drug information was verified from patients' notes when available.
Results
Of the 87 patients who completed the study,    The findings for men and women were analysed six were excluded prior to analysis when they were found to have used prohibited medseparately. Demographic and biochemical measures were compared between treatment ications; this left 38 men (19 in each group) and 43 women (15 and 28 in groups 1 and groups by one way analysis of variance after log transformation as appropriate, or Mann-2, respectively) available for evaluation. The demographic data are summarised in table 1. Whitney test. Physical activity grades were compared by the 2 test after pooling categories The only significant difference between men in groups 1 and 2 was a higher mean FVC of when needed to achieve sufficient numbers for analysis. The independent dose-response effect 0.57 l in group 1 (95% CI 0.09 to 1.05; p <0.03). The significant differences between of three continuous measures of inhaled steroid use (standardised cumulative dose in mg/ women in group 2 compared with group 1 were mean age (6.4 years older; 95% CI 2.8 to 10.0, day.years, total days of use, and average daily dose over the last 12 months) on bone mineral p=0.001), age at menarche (one year earlier; 95% CI −1.82 to −0.18, p <0.03), longer density was assessed using multiple linear regression analysis (SAS version 6, SAS Institute duration of asthma (median 12.5 versus 8 years, p=0.001), and greater number of pack years Inc, Cary, North Carolina, USA). Initially, the effect of a number of potential confounding smoking amongst those who had ever smoked (median 4.5 versus 1.25; p=0.01). The differvariables was assessed using stepwise and backward selection procedures; these included age, ences between the two groups in life time total dose of contraceptive oestrogens and proweight, pack years of smoking, units of alcohol per week, and activity grade. FEV 1 % predicted gesterone, number of full term pregnancies, and total number of months breast feeding was also fitted as a proxy measurement for asthma severity. Age at menarche and life time were not statistically significant. total dose of oestrogen and progesterone use were fitted for women. A level of pΖ0.15 was assumed in order not to reject variables with a       None of the patients in group 1 had ever borderline effect on BMD. Prednisolone use was then fitted as life time number of courses received inhaled or systemic steroids. Inhaled and oral steroid use for patients in group 2 is and, being the main potential confounder of group.bmj.com on June 19, 2017 -Published by http://thorax.bmj.com/ Downloaded from linear regression there was no significant doseresponse effect of cumulative or current daily dose of inhaled steroids on the serum concentration of osteocalcin. summarised in table 2. Forty one of the 47 patients taking an inhaled steroid were using beclomethasone dipropionate (BDP), one hav-   ing taken budesonide in the past; the other six There were no significant differences in mean were currently taking budesonide all having bone density values between the two treatment taken BDP in the past. Of the 47 patients, 36 groups for either men or women (table 3) . were using a metered dose inhaler and 11 a Amongst patients in group 2 there was no dry powder inhaler (nine BDP, two budesonsignificant difference in BMD between those ide). Six of 19 men and 14 of 28 women had who had received oral steroids in the past and received oral steroids, invariably prednisolone, those who had not, apart from BMD of the in the past with a mean of 1.33 and 2.46 radius which was higher in women who were courses, respectively (giving a mean of 0.42 past oral steroid users (difference 0.039 g/cm 2 and 1.14 courses for all men and all women (95% CI 0.002 to 0.076); p=0.04). Before on inhaled steroids). None of the patients had adjustment for potential confounders there was received intravenous steroids, one man had a significant negative dose-response relationhad intramuscular steroids for hayfever on two ship between bone density and cumulative dose occasions in the last five years, and two patients of inhaled steroid at the two spine sites in (one man) in group 1 and six (three men) in women (L2-L4 (n=43): estimate of slope group 2 were currently using dermal steroids −0.016 (95% CI −0.004 to −0.03), p=0.01; (past users numbered one (man) and 11 (four lateral B3 (n=42): estimate of slope −0.023 men), respectively).
 
(95% CI 0.009 to −0.030), p=0.002; fig 1) . Frequency of physical activity and grading of self assessed fitness and strength were similar for most measures in the two groups except that more women in group 2 were in the lower   In women, multivariate linear regression categories for walking frequency (grades 1+2+3; 40% versus 71% for groups 1 and 2, showed that the negative association between standardised cumulative inhaled steroid dose respectively, difference 31% (95% CI 1 to 62), p <0.05). None of the patients had avoided and bone mineral density at the spine was independent of the number of prednisolone milk products in the past. Having completed our primary analysis we carried out two further analyses. Firstly, when the analysis was recomputed excluding the two women on the highest cumulative dose of inhaled steroid the estimates of the slopes for the two spine sites (L2-L4 and B3) were 0.0001 (95% CI −0.018 to 0.018) g/cm 2 , p=0.99 and −0.0098 (95% CI −0.031 to 0.012) g/cm 2 , p=0.36, respectively. Secondly, when we repeated the multivariate analysis of the two spine sites for women excluding the 15 patients who had not had inhaled steroids, the estimates for the slopes did not change markedly but were no longer statistically significant (estimates of slopes for L2-L4 and B3 were −0.012 (95% CI −0.026 to 0.0012) g/cm 2 ; p=0.09 and −0.016 (95% CI −0.033 to 0.002) g/cm 2 ; p= 0.10, respectively, for each mg/day.year inhaled steroid). In men, none of the measures of inhaled Figure 1 Univariate regressions of bone mineral density steroid use showed a significant relation to bone
(BMD) of (A) L2-L4 (n=43) and (B) B3 (n=42) on
density at any of the skeletal sites. Bone density cumulative dose of inhaled steroids in women.
at the L2-L4 and B3 spine and distal radius were significantly associated with weight (estimates of 0.0044 (95% CI 0.0001 to 0.0087) courses and the variables shown in table 4. g/cm 2 , p=0.04; 0.0095 (95% CI 0.0051 to These variables were included in the model 0.0139) g/cm 2 , p=0.001; and 0.0034 (95% CI as potential confounders because they had a 0.0014 to 0.0054) g/cm 2 , p=0.001, resignificant effect (p<0.15) on the total variance spectively, per kg increase in body weight). of the model when added or removed during Self assessed fitness was significantly associated the stepwise and backward selection procedure. with bone density at the two spine sites with For each mg/day.year of inhaled steroid use estimates for the slope of 0.0622 (95% CI there was a decrease in bone density of 0.015 0.0039 to 0.1205) g/cm 2 , p <0.04, and 0.0745 (95% CI 0.002 to 0.028) and 0.017 (95% CI (95% CI 0.0106 to 0.1384) g/cm 2 , p <0.03, per 0.002 to 0.031) g/cm 2 at the L2-L4 and B3 category of fitness. No variable was significantly sites, respectively (p=0.03 for both). When associated with bone density at the femoral expressed as standard deviations both equate neck in men. to a reduction in BMD of 0.11 SD per mg/ No fractures were detected in women on day.year inhaled steroid use (L2-L4: 95% CI vertebral morphometry of spine radiographs. 0.01 to 0.22 SD; B3: 95% CI 0.02 to 0.21 SD). Six men in group 1 and two in group 2 had a Bone density at the B3 site was independently total of 13 vertebral fractures; these were not related to life time progesterone dose such that related to bone density or inhaled steroid dose. a two fold increase in progesterone dose would result in a 6 × 10 −6 g/cm 2 increase in BMD (p <0.03). None of the other measures of inhaled Discussion steroid use was significantly related to bone In this study there was no difference in mean BMD values for men or women who were and density in the spine and none was related to Explanatory variables resulting in a significant (p<0.15) change in residual variance during stepwise or backward selection modelling are shown with estimate, 95% confidence intervals (CI) and p value for the slope.
group.bmj.com on June 19, 2017 -Published by http://thorax.bmj.com/ Downloaded from were not using inhaled steroids. There was, any site. These data suggest that asthma severity was not an important determinant of however, a statistically significant reduction in BMD in women with increasing dose of inhaled BMD in our patients.
Women in the inhaled steroid group were steroid, equivalent to a 0.11 SD reduction in BMD of the lumbar spine for every year's use less likely to smoke than those in the nonsteroid group, although those who did smoked of 1000 g/day inhaled steroid after correction for confounding factors. Women using inhaled more cigarettes per day. The positive relationship between smoking and wrist BMD in steroids also had significantly lower serum osteocalcin concentrations.
women was surprising and may be a chance finding as smoking has been associated with Cross sectional group comparisons are susceptible to confounding by differences in age, lower values of BMD, at least in postmenopausal women.
34 menopausal status, physical activity, and previous drug use including, in the case of asthma, Although the relation between BMD and inhaled steroid use was statistically significant, systemic steroid use. Less well characterised are the effects of alcohol, smoking, diet, parity, it was influenced by two women who had received high cumulative doses of inhaled sterand past use of contraceptive hormones. 27 In the present study we reduced the effects of age oids (fig 1) . One of the women had never received oral steroids whilst the other had reand menopause by only including patients aged 20-40 years when bone density is reasonably ceived a total of six courses (life time dose 1200 mg prednisolone) which would be taken stable, 28 and by excluding women who were not menstruating regularly. Other factors al-into account in the multivariate analysis. Statistical significance was lost when the multilowed for in the analysis were physical activity, weight, smoking, alcohol consumption, oral variate regressions for the two spine sites was recomputed excluding the data from these contraceptive use, and parity.
Past use of systemic steroids is probably the women. We also tested whether the estimate for the slope for the relationship between inhaled most important potential confounder in this type of study. It would have been ideal to have steroid dose and bone density was altered by excluding the patients who had never had excluded any patients with previous exposure to corticosteroids but this was difficult in practice. corticosteroids. The estimates were largely unaltered although they were no longer stat-(Over 1000 patients were screened to obtain the current numbers.) We therefore allowed istically significant due to the smaller numbers.
Although our findings could be spurious we patients with limited prior exposure to systemic steroids into the study. Less than half the think this is very unlikely since BMD was our primary end point, and the fact that it was the patients had had oral steroids previously with no courses exceeding two weeks in length or lumbar spine in women that was affected is biologically plausible in the light of oral steroid doses above 40 mg prednisolone/day. We also allowed for previous steroid use in the re-studies. Our findings need to be confirmed in studies that include more patients on high doses gression analysis. Studies in patients treated for Cushing's syndrome 29 or following cessation of inhaled steroids. The finding of lower osteocalcin concenof long term oral steroids for sarcoidosis 30 suggest that, once treatment stops, bone density trations among patients using inhaled steroids is consistent with other studies. 6 18 Osteocalcin returns towards predicted levels, at least in patients under 45 years of age. Only one female is considered to be a marker of osteoblast function although its exact role in bone metapatient had had oral steroids in the six months before the study. Previous use of nasal steroids bolism is unclear. 35 There was no correlation between osteocalcin concentration and bone was an exclusion criterion. Dermatological steroids were allowed since systemic effects have density, which may be because osteocalcin levels reflect recent changes in bone turnover. only been seen when topical steroids are applied to large areas of broken skin with occlusion 31 32 An association between inhaled steroid use and BMD was only seen in women. This may which was not the case with our subjects. The long term effects of skin steroids on bone dens-be a reflection of the relatively small numbers, although a similar sex difference was reported ity are not known.
We also considered whether confounding by in another study. 5 Inhaled steroids may alter bone metabolism through an effect on endoasthma severity might result in reduced BMD among users of inhaled steroids by inhibiting genous sex hormones, in particular, oestrogen.
Serum oestrone concentrations were lower physical activity or through delayed onset of puberty. The range and frequency of physical in postmenopausal women using systemic corticosteroids than in those not using them in activities between the two groups were similar, except that women in the inhaled steroid group a study by Marshall et al. 36 Oestrogen is thought to reduce bone resorption, 37 although contended to walk for less time than those in the non-steroid group. Whether this is relevant is centrations of urinary deoxypyridinoline, a marker of bone resorption, were unchanged in uncertain since bone density is stimulated to a greater extent by exercises that involve skeletal our study.
All the vertebral fractures were seen in men loading or a high impact component such as jumping. 33 Delayed puberty was not relevant and there was no relationship between the vertebral fractures and inhaled steroid use or since women in the inhaled steroid group had an earlier menarche. Finally, when we included bone density. This was surprising but may reflect a greater involvement by young men in FEV 1 % predicted as a measure of asthma severity in the regression model it was not a occupations or leisure activities which carry a higher risk of fractures. significant independent predictor of BMD at 
